Company Overview
Envision Pharma Limited is listed at the official companies registry as Active Private Limited Company. The company was incorporated on Monday 15 July 2002, so this is a well established company. Envision Pharma Limited has been in business for 23 years and 9 months. The accounts status is audit exemption subsidiary and the accounts are next due on Wednesday 31 December 2025.
Registered Address

Envision House, 5 North Street, Horsham, West Sussex, RH12 1XQ
Credit Reports Available

These credit rating reports are available now:


Credit Analysts Report
Get Report >>

Standard Credit Report
Get Report >>

Basic Credit Report
Get Report >>

24/7 credit rating data feed - no UK company credit reports are updated faster

Companies House Data
Company NameENVISION PHARMA LIMITED
Company Number04486293
Registered Office AddressEnvision House
 5 North Street
 RH12 1XQ
Company CategoryPrivate Limited Company
Company StatusActive
Country of OriginUnited Kingdom
Incorporation Date15/07/2002
Accounting Reference Date Day31
Accounting Reference Date Month12
Accounts Next Due Date30/09/2026
Accounts Last Made Up Date31/12/2024
Accounts Account CategoryAUDIT EXEMPTION SUBSIDIARY
Returns Next Due Date13/08/2016
Returns Last Made Up Date16/07/2015
Directors & Members
Show Resigned
Adam Deutsch - Director
(American, 56 years old, born December 1970)
Appointed 20 August 2024
 Active
Stanford Rudnick - Director
(American, 43 years old, born August 1983)
Appointed 09 December 2024
 Active
Secretaries
Show Resigned
Other Company Directorships
Adam Deutsch
20SENSES LIMITED
90TEN GROUP LIMITED
90TEN LTD.
ALLIGENT BIOPHARM CONSULTING (EUROPE) LIMITED
CURO CONSULTING LIMITED
ELEVATE SCIENTIFIC SOLUTIONS LIMITED
ELOQUENT SCIENTIFIC SOLUTIONS LIMITED
ENGAGE SCIENTIFIC SOLUTIONS LIMITED
ENVISION MARKET ACCESS SOLUTIONS LIMITED
ENVISION PHARMA BIDCO LIMITED
ENVISION PHARMA FINCO LIMITED
ENVISION PHARMA GROUP LIMITED
ENVISION PHARMA HOLDCO LIMITED
ENVISION PHARMA MIDCO LIMITED
EVIDENCE FINCO LIMITED
EVIDENCE MIDCO LIMITED
EVIDENCE SCIENTIFIC SOLUTIONS LIMITED
EXCEL SCIENTIFIC SOLUTIONS LIMITED
OKRA HOLDINGS LIMITED
OKRA TECHNOLOGIES LIMITED
PENNSIDE PARTNERS UK LIMITED
TOUCH CREATIVE DESIGN LIMITED
UMOTIF LIMITED
Stanford Rudnick
20SENSES LIMITED
90TEN GROUP LIMITED
90TEN LTD.
ALLIGENT BIOPHARM CONSULTING (EUROPE) LIMITED
CURO CONSULTING LIMITED
ELEVATE SCIENTIFIC SOLUTIONS LIMITED
ELOQUENT SCIENTIFIC SOLUTIONS LIMITED
ENGAGE SCIENTIFIC SOLUTIONS LIMITED
ENVISION MARKET ACCESS SOLUTIONS LIMITED
ENVISION PHARMA BIDCO LIMITED
ENVISION PHARMA FINCO LIMITED
ENVISION PHARMA GROUP LIMITED
ENVISION PHARMA HOLDCO LIMITED
ENVISION PHARMA MIDCO LIMITED
EVIDENCE FINCO LIMITED
EVIDENCE MIDCO LIMITED
EVIDENCE SCIENTIFIC SOLUTIONS LIMITED
EXCEL SCIENTIFIC SOLUTIONS LIMITED
EXEEVO, INC.
OKRA HOLDINGS LIMITED
OKRA TECHNOLOGIES LIMITED
PENNSIDE PARTNERS UK LIMITED
TOUCH CREATIVE DESIGN LIMITED
Balance Sheet Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2015 31-Dec-2014
Balance Sheet
Fixed Assets 1,660,934 1,660,934 947,821
Current Assets 7,402,251 7,402,251 8,593,268
Creditors Due Within One Year 7,570,101 7,570,101 8,589,514
Working Cap -167,850 -167,850 3,755
Total Assets Less Current Liabilities 1,493,084 1,493,084 951,575
Long-term Liabilities 71,497 71,497 1
Net Assets 1,421,587 1,421,587 951,576
Share Capital & Reserves
Share Cap 15,367 15,367 15,367
Profit & Loss Reserves 1,269,175 1,269,175 936,209
Other Reserves 137,045 137,045 0
Shareholders Funds 1,421,587 1,421,587 951,576
Common Size Financial Analysis Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2015 31-Dec-2014
Tangible Fixed Assets - - -
Fixed Assets 18.3% 18.3% 9.9%
Stocks Inventory 0.0% 0.0% 0.0%
Debtors 3.6% 3.6% 3.7%
Cash Bank In Hand 11.9% 11.9% 14.5%
Current Assets 81.7% 81.7% 90.1%
Creditors Due Within One Year 83.5% 83.5% 90.0%
Net Current Assets Liabilities -1.9% -1.9% 0.0%
Creditors Due After One Year 0.8% 0.8% 0.0%
Accruals Deferred Income - - -
Provisions For Liabilities Charges - - -
Net Assets Liabilities Including Pension Asset Liability 15.7% 15.7% 10.0%
Called Up Share Capital 0.2% 0.2% 0.2%
Share Capital Allotted Called Up Paid 0.2% 0.2% 0.2%
Profit Loss Account Reserve 14.0% 14.0% 9.8%
Shareholder Funds 15.7% 15.7% 10.0%
Capital Employed - - -
Total Assets Less Current Liabilities 16.5% 16.5% 10.0%
Financial Ratio Analysis Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2015 31-Dec-2014
Liquidity Ratio 1.0 1.0 1.0
Solvency Ratio 1.2 1.2 1.1
Reserves to Assets 0.1 0.1 0.1
Secured Creditors Unlock full report
Mortgages Charges 6
Mortgages Outstanding 3
Mortgages Part Satisfied 0
Mortgages Satisfied 3
Assets and Debt Analysis Unlock full report
Accounts Date 31-Dec-2024 31-Dec-2015 31-Dec-2014
Assets 9,063,185 9,063,185 9,541,089
Debt 7,641,598 7,641,598 8,589,513
Net Assets/Debt 1,421,587 1,421,587 951,576

The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.

As at the balance sheet date current liquid assets were slightly less than short term debt. We would normally view a company broadly neutrally for this. Total reserves including retained profitability and movement in reserves appeared positive. We would normally view a company positively for this. For the size of the company inferred by the balance sheet this level of net assets suggests total debts and obligations were moderately well covered.

Unlock full report  The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.As at the balance sheet date current liquid assets were slightly less than short term debt. We would normally view a company broadly neutrally for this. Total reserves including retained profitability and movement in reserves appeared positive. We would normally view a company positively for this. For the size of the company inferred by the balance sheet this level of net assets suggests total debts and obligations were moderately well covered.   The following is based on the accounts data presented in this report sourced from Companies House, however the company has filed later accounts. Our analysis of the latest account can be viewed by unlocking our full report.As at the balance sheet date current liquid assets were slightly less than short term debt. We would normally view a company broadly neutrally for this. Total reserves including retained profitability and movement in reserves appeared positive. We would normally view a company positively for this. For the size of the company inferred by the balance sheet this level of net assets suggests total debts and obligations were moderately well covered.

This review of public record balance sheet and company status information is presented under the terms of Open Government Licence and is for informational purposes only, is general in nature, and is not intended as an opinion or advice for any specific circumstances. The commentary and the colour band score is not a credit rating or credit risk assessment.

This review does not constitute a full credit rating or credit risk assessment based on the full analysis and credit score algorithms used in our credit reports. A full credit report may also provide information relating to trade payment history and county court or court judgments if any.

Public Record Information Unlock full report
Exact Court Judgements
Period of Months Last 12m 13-24m 25-36m 37-48m 49-60m 61-72m
Number of Exact CCJS X Y Y X X Y
Value of Exact CCJS YXY YK S S X KX
Supplier Credit Limits Unlock full report
Date Sector Notified Amount Terms
XK-SXY XKXYXK SXSKXYXK £X,000 XS XYSKS
SK-SYY SKXYXKYKKY KSXX KKXXYXS £YY,000 YS XYSKS SK YXXSXS
YK-SXY XKXYXYYK SXSXYXK £SX,000 XS XYSKS
Payment Records Unlock full report
Payment Records from it's suppliers' company ledger show how a company is paying its suppliers

Payment Analysis

Total Invoices Paid Before
30 days due		 Paid After
30 days due		 Owing Before
30 days due		 Owing after
30 days due
XYX SX K YX X
Company Valuation Analysis Unlock full report

Going Concern Valuation

The going concern valuations value the company on the basis that it continues to trade without the threat of liquidation for the foreseeable future. These valuations are primarily profit and cashflow based.

Valuations Valuation Measures
Estimated High Value £XSI,000 Retained Profit £YX,000
Estimated Mid Value £YY,000 EBIT £SY,000
Estimated Low Value £X,000 EBITDA £SSX,000

Liquidation Valuation

The liquidaton valuation values the company as if it were to cease trading and assets were subject to rapid disposal to cover liabilities. This valuation is primarily asset based.

Valuations Valuation Measures
Estimated High Value £XY,000 Total Assets £XIX,000
Estimated Mid Value £Y,000 Net Assets £YX,000
Estimated Low Value £S,000 Tangible Equity £SX,000

The above valuations are based on our own algorithms and take no account of many factors that can influence actual valuations realized and should not therefore be assumed to be accurate.
Credit Status Checklist Unlock full report
Business Growth Please purchase a report to see true comments
EBITDA Purchase a report to see true comments
Dividends Please purchase a report to see true comments about this company
Retained Profits Retained Profits for this company
Debt Interest Debt Interest for this company
Cash Flow Cash Flow for this company
CCJs CCJs for this company
Age of Company Age of Company for this company
Solvency Solvency for this company
Secured Creditors Secured Creditors for this company
Ownership Ownership for this company


First Report Score: (0-10) X
Financial Status Guide:
10 Very Strong
9 Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical

Risk Score Trend

Risk Rating Unlock full report

This is the credit risk assessment used by one of the top UK credit reference agencies.

Risk Score (1-100) X
Risk Band Description XXMXMXMX SISX
Risk Assessment Meeting of Creditors
Credit Rating XSKX
Altman Z Score Credit Risk Rating Unlock full report

There have been many bankruptcy predictors developed, however none has been so thoroughly tested and broadly accepted as the Altman Z-Score.

Z Score X
Risk Band XY
Risk Band Description The Z Score is not used for small companies where full accounts are not filed because profit and loss account items are required to calculate the score.

Z Score Bands

1 Low Risk 3.00 and above
2 Caution 2.63 - 2.99
3 Risk of Failure within 2 years 1.24 - 2.62
4 High Probability Failure Below 1.24
Other Business around RH12 1XQ
CURO CONSULTING LIMITED
ENVISION HOUSE, 5 NORTH STREET, HORSHAM, WEST SUSSEX, RH12 1XQ
ENVISION MARKET ACCESS SOLUTIONS LIMITED
5 NORTH STREET, HORSHAM, WEST SUSSEX, RH12 1XQ
EVIDENCE SCIENTIFIC SOLUTIONS LIMITED
ENVISION HOUSE, 5 NORTH STREET, HORSHAM, WEST SUSSEX, RH12 1XQ
ENGAGE SCIENTIFIC SOLUTIONS LIMITED
ENVISION HOUSE, 5 NORTH STREET, HORSHAM, WEST SUSSEX, RH12 1XQ
ENVISION PHARMA HOLDCO LIMITED
ENVISION HOUSE, 5, NORTH STREET, HORSHAM, WEST SUSSEX, RH12 1XQ
TOUCH CREATIVE DESIGN LIMITED
ENVISION HOUSE, 5 NORTH STREET, HORSHAM, WEST SUSSEX, RH12 1XQ
EXCEL SCIENTIFIC SOLUTIONS LIMITED
ENVISION HOUSE, 5 NORTH STREET, HORSHAM, WEST SUSSEX, RH12 1XQ
ALLIGENT BIOPHARM CONSULTING (EUROPE) LIMITED
ENVISION HOUSE, 5 NORTH STREET, HORSHAM, WEST SUSSEX, RH12 1XQ
ENVISION PHARMA BIDCO LIMITED
ENVISION HOUSE, 5 NORTH STREET, HORSHAM, WEST SUSSEX, RH12 1XQ
ENVISION PHARMA FINCO LIMITED
ENVISION HOUSE, 5 NORTH STREET, HORSHAM, WEST SUSSEX, RH12 1XQ
Document Filings
Satisfaction of charge 044862930004 in full
Satisfaction of charge 044862930005 in full
Satisfaction of charge 044862930006 in full
Consolidated accounts of parent company for subsidiary company period ending 31/12/24
Audit exemption statement of guarantee by parent company for period ending 31/12/24
Notice of agreement to exemption from audit of accounts for period ending 31/12/24
Confirmation statement made on 16 July 2025 with no updates
Director's details changed for Stanford Benjamin Rudnick on 9 December 2024
Appointment of Stanford Benjamin Rudnick as a director on 9 December 2024
Termination of appointment of Howard Collins Miller Iii as a director on 31 December 2024
Termination of appointment of Joshua Hollis Korth as a director on 15 November 2024
Appointment of Mr. Adam Brent Deutsch as a director on 20 August 2024
Consolidated accounts of parent company for subsidiary company period ending 31/12/23
Notice of agreement to exemption from audit of accounts for period ending 31/12/23
Audit exemption statement of guarantee by parent company for period ending 31/12/23
Confirmation statement made on 16 July 2024 with no updates
Director's details changed for Joshua Hollis Korth on 14 December 2021
Change of details for Envision Pharma Holdco Limited as a person with significant control on 16 July 2016
Appointment of Mr Howard Collins Miller Iii as a director on 12 September 2023
Termination of appointment of Margaret Heim as a director on 2 August 2023
Consolidated accounts of parent company for subsidiary company period ending 31/12/22
Notice of agreement to exemption from audit of accounts for period ending 31/12/22
Terms and Conditions Cancellations Contact Us

In using this service you agree to the Terms and Conditions

© 2026 Check Free